Retinoblastoma treatment: Utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-d-glucose (2-FG), to target the chemoresistant hypoxic regions in LH BETAT AG retinal tumors

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 2, 2012, Pages 996-1002

  Piña, Yolanda ^a   Decatur, Christina ^a   Murray, Timothy G ^a   Houston, Samuel K ^a   Lopez Cavalcante, Milena ^a   Hernandez, Eleut ^a   Celdran, Magda ^a   Shah, Nikesh ^a   Feuer, William ^a   Lampidis, Theodore ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HYPOXIA; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETINA BLOOD VESSEL; RETINOBLASTOMA; TRANSGENIC MOUSE; TUMOR VOLUME; VASCULARIZATION; ANIMAL; ANOXIA; DRUG EFFECT; EXPERIMENTAL NEOPLASM; GLYCOLYSIS; PATHOLOGY; RETINA TUMOR; TREATMENT OUTCOME;

ANIMALS; ANOXIA; FLUORODEOXYGLUCOSE F18; GLYCOLYSIS; MICE; NEOPLASMS, EXPERIMENTAL; RADIOPHARMACEUTICALS; RETINAL NEOPLASMS; RETINOBLASTOMA; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84859941115     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-8265     Document Type: Article

References (31)

1. Pendergrass TW, Davis S. Incidence of retinoblastoma in the United States. Arch Ophthalmol. 1980;98:1204-1210.
2. Tamboli A, Podgor MJ, Horm JW. The incidence of retinoblastoma in the United States: 1974 through 1985. Arch Ophthalmol. 1990; 108:128-132.
3. Abramson DH. Retinoblastoma in the 20th century: past success and future challenges the Weisenfeld lecture. Invest Ophthalmol Vis Sci. 2005;46:2683-2691.
4. Laurie NA, Schin-Shih C, Dyer MA. Targeting MDM2 and MDMX in retinoblastoma. Curr Cancer Drug Targets. 2007;7:689-695.
5. Boutrid H, Jockovich ME, Murray TG, et al. Targeting hypoxia, a novel treatment for advanced retinoblastoma. Invest Ophthalmol Vis Sci. 2008;49:2799-2805.
6. Maschek G, Savaraj N, Priebe W, et al. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res. 2004;64:31-34.
7. Boutrid H, Pina Y, Cebulla CM, et al. Increased hypoxia following vessel targeting in a murine model of retinoblastoma. Invest Ophthalmol Vis Sci. 2009;50:5537-5543.
8. Maher JC, Krishan A, Lampidis TJ. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother Pharmacol. 2004;53:116-122.
9. Lampidis TJ, Kurtoglu M, Maher JC, et al. Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing "hypoxic tumor cells". Cancer Chemother Pharmacol. 2006;58: 725-734.
10. Boutrid H, Pina Y, Cebulla C, et al. Vessel targeting increases hypoxia in a murine model of retinoblastoma. Invest Ophthalmol Vis Sci. 2009;50:5537-5543.
11. Merchan JR, Kovacs K, Railsback JW, et al. Antiangiogenic activity of 2-deoxy-D-glucose. PLoS One. 5:e13699.
12. Berman EL, Donaldson CE, Giblin M, Martin FJ. Outcomes in retinoblastoma. 1974-2005: the Children's Hospital, Westmead. Clin Experiment Ophthalmol. 2007;35:5-12.
13. Rouic LL, Aerts I, Levy-Gabriel C, et al. Conservative treatments of intraocular retinoblastoma. Ophthalmology. 2008;115:1405-1410, 1410.e1-2.
14. Schefler AC, Cicciarelli N, Feuer W, Toledano S, Murray TG. Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation. Ophthalmology. 2007;114:162-169.
15. Windle JJ, Albert DM, O'Brien JM, et al. Retinoblastoma in transgenic mice. Nature. 1990;343:665-669.
16. Jockovich ME, Pina Y, Alegret A, Cebulla C, Feuer W, Murray TG. Heterogeneous tumor vasculature in retinoblastoma: implications for vessel targeting therapy. Retina. 2008;28:S81-S86.
17. Varia MA, Calkins-Adams DP, Rinker LH, et al. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol. 1998; 71:270-277.
18. Jockovich ME, Murray TG, Escalona-Benz E, Hernandez E, Feuer W. Anecortave acetate as single and adjuvant therapy in the treatment of retinal tumors of LH(BETA)T(AG) mice. Invest Ophthalmol Vis Sci. 2006;47:1264-1268.
19. Nehls V, Drenckhahn D. Heterogeneity of microvascular pericytes for smooth muscle type alpha-actin. J Cell Biol. 1991;113:147-154.
20. Tanaka F, Otake Y, Yanagihara K, et al. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res. 2001;7:3410-3415.
21. Pina Y, Boutrid H, Schefler A, et al. Blood vessel maturation in retinoblastoma tumors: spatial distribution of neovessels and mature vessels and its impact on ocular treatment. Invest Ophthalmol Vis Sci. 2009;50:1020-1024.
22. Jockovich ME, Bajenaru ML, Pina Y, et al. Retinoblastoma tumor vessel maturation impacts efficacy of vessel targeting in the LH-(BETA)T(AG) mouse model. Invest Ophthalmol Vis Sci. 2007;48: 2476-2482.
23. Konerding MA, Miodonski AJ, Lametschwandtner A. Microvascular corrosion casting in the study of tumor vascularity: a review. Scanning Microsc. 1995;9:1233-1243; discussion 1243-1234.
24. Darland DC, D'Amore PA. Blood vessel maturation: vascular development comes of age. J Clin Invest. 1999;103:157-158.
25. Gee MS, Procopio WN, Makonnen S, Feldman MD, Yeilding NM, Lee WM. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am J Pathol. 2003; 162:183-193.
26. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401-410.
27. Chan HS, Gallie BL, Munier FL, Beck Popovic M. Chemotherapy for retinoblastoma. Ophthalmol Clin North Am. 2005;18:55-63, viii.
28. Geschwind JF, Georgiades CS, Ko YH, Pedersen PL. Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma. Expert Rev Anticancer Ther. 2004;4:449-457.
29. Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta. 2002;1555: 14-20.
30. Merchan JR, Kovacs K, Railsback JW, et al. Antiangiogenic activity of 2-deoxy-D-glucose. PLoS One. 2010;5:e13699.
31. Pina Y, Decatur C, Murray T, et al. Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LH(BETA)T(AG) retinal tumors. Clin Ophthalmol. 2011;5:337-343.